VEGFA and neoplasm: The rationale for the combination of VEGF and PD-1 inhibitors in HCC is related to the effect of impaired VEGF-mediated immunosuppression within the tumor and its microenvironment by VEGF inhibitors, leading to enhanced anti-PD-1 efficacy [151,152].